Medical Editor: John P. Cunha, DO, FACOEP
Cerubidine (daunorubicin) is a cancer (antineoplastic) medication used in the treatment of leukemia (blood cancer). Cerubidine is available in generic form. Common side effects of Cerubidine include nausea, vomiting, constipation, diarrhea, and loss of appetite. Cerubidine may cause urine to turn a reddish color. This is a normal, harmless effect of Cerubidine and should not be mistaken for blood in the urine. Temporary hair loss is a common side effect of Cerubidine. Normal hair growth should return after treatment with Cerubidine has ended.
Dosage of Cerubidine is determined by a physician and the drug is administered in a clinical setting. Cerubidine may interact with cyclophosphamide, methotrexate, or "live" vaccines. Tell your doctor if you have had previous treatment with doxorubicin, doxorubicin liposomal, daunorubicin, daunorubicin liposomal, idarubicin, or mitoxantrone. Because there is a maximum amount of these medications that should be administered to an individual, you may not be able to use Cerubidine. Tell your doctor all medications and supplements you use. Cerubidine is not recommended for use during pregnancy. It may harm a fetus. If you become pregnant or think you may be pregnant, tell your doctor. Males and females using this drug should use birth control (e.g., birth control pills, condoms) during treatment; consult your doctor. It is unknown if this drug passes into breast milk. Because of the possible risk to the infant, breastfeeding while using this drug is not recommended.
Our Cerubidine (daunorubicin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
If you experience any of the following serious side effects from daunorubicin, contact your doctor immediately:
- an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
- decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
- congestive heart failure (difficulty breathing, fluid retention, chest pain);
- tissue or vein reactions near the site of administration;
- liver damage (abdominal pain, yellowing of the skin or eyes);
- nausea, vomiting, diarrhea, or loss of appetite;
- inflamation or sores inside the mouth, throat, or intestines;
- rash, itching, or hives;
- fever, chills, or other signs of infection; or
- increased levels of uric acid in the body (joint pain and stiffness).
Other, less serious side effects may be more likely to occur. Continue taking daunorubicin and talk to your doctor if you experience:
- temporary hair loss; or
- red colored urine for 1 or 2 days following a dose.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Cerubidine (Daunorubicin)
Dose-limiting toxicity includes myelosuppression and cardiotoxicity (See WARNINGS). Other reactions include:
Gastrointestinal:Acute nausea and vomiting occur but are usually mild. Antiemetic therapy may be of some help. Mucositis may occur 3 to 7 days after administration. Diarrhea and abdominal pain have occasionally been reported.
Read the entire FDA prescribing information for Cerubidine (Daunorubicin)